X
XENOCOR PHARMALAB PRIVATE LIMI
Our four primary XmAb Fc domains are designed to improve therapeutic antibody performance by enhancing immune regulation, cytotoxic potency, or circulating half ...|Redesigning Antibody and Cytokine Drugs from the Ground Up. To create its XmAb protein engineering platform, Xencor precisely alters an Fc domain — the stem of ...|Xencor is committed to creating new antibody drugs that improve patient outcomes. Please use the contact form below if you have any questions or requests.|Clinical trials are research studies that are designed to determine whether a potential medicine is safe and effective for patients.|Xencor is expanding the therapeutic boundaries of antibody and cytokine drugs. Powered by its XmAb® protein engineering platform, Xencor is developing a broad ...|Xencor is conducting a Phase 1 monotherapy study of plamotamab with subcutaneous dose escalations in patients with relapsed or refractory non-Hodgkin lymphoma.|Xencor's Xtend™ Fc domains increase binding affinity to the receptor FcRn. FcRn is present inside lysosomes in endothelial cells lining the blood vessels ...|The Key to Antibody Immune Function and Structure. Xencor's proprietary XmAb protein engineering platform creates subtle, precise alterations to an antibody's ...|We have assembled a highly talented group from diverse backgrounds and disciplines to execute our business plan and shape our future. Xencor employees value new ...
Country/Area ：India
Company Email ：info@xencor.com
Industry ：HealthcarePharmaceuticals
Company website ：*****
Company phone ：(626) 305-5900
Established ：1997
Company Revenue ：$164,579,000
Number of employees ：281
SIC Code ：28283
NAICS Code ：32325
Company News
Things Look Grim For Xencor, Inc. (NASDAQ:XNCR) After Today's Downgrade
Nov 13, 2023
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...
Nov 13, 2023
Xencor, Inc. (XNCR) Q3 2023 Earnings Call TranscriptNov 8, 2023
Xencor, Inc. (NASDAQ:NASDAQ:XNCR) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ETCompany ParticipantsCharles Liles - Head, Corporate...
Nov 8, 2023Xencor Reports Third Quarter 2023 Financial ResultsNov 7, 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights. “Today we are announcing measures to strengthen our balance sheet and maximize our focus on the most promising programs created with
Nov 7, 2023Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 MillionNov 7, 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris® (ravulizumab-cwvz) and from MorphoSys AG on sales of Monjuvi® (U.S.)/Minjuvi® (ex-U.S.) (tafasitamab-cxix) to OMERS, one of Canada’s largest defined benefit pension plans. Un
Nov 7, 2023Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual MeetingNov 3, 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from multiple preclinical-stage XmAb® programs at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego. “Xencor aims to stay on the leading edge of molecular engineering, using and improving upon our XmAb technologies to create molecules
Nov 3, 2023Business Info
CIN ：U29299KA2007PTC042079
Registered State ：Karnataka
Registrar Of Companies ：RoC-Bangalore
Category ：Company limited by Shares
Sub Category ：Non-govt company
Company Class ：Private
Company Status ：Active
Registered Office Address ：NO. 17/1(17/2) 10TH MAIN S P MAIN ROAD, KADIRENAHALLI BANGALORE Bangalore KA IN 560070
Authorized Cap ：1000000.00
Paidup Capital ：1000000.00
Web Summary
Q1: What is the address of Xencor's headquarters?
A1: The address of Xencor's headquarters is 465 North Halstead Street, Suite 200 Pasadena, CA 91107.
Q2: What type of products does Xencor develop and commercialize?
A2: Xencor develops and commercializes therapeutic antibody drug candidates using its XmAb protein engineering platform, which includes bispecific Fc domains, cytotoxic Fc domains, immune inhibitor Fc domains, and Xtend Fc domains.
Q3: In what industries is Xencor's pipeline focused on treating?
A3: Xencor's pipeline is focused on treating cancer, autoimmune disorders, and infectious diseases.
Q4: What services does Xencor provide to its partners?
A4: Xencor provides a plugandplay approach to creating differentiated antibody drug candidates by licensing its highperformance Fc domains to partners interested in therapeutic targets outside of Xencor's areas of focus. This includes conducting limited research and development to create potential candidates for further development and commercialization by partners.
Q5: Who are some of the select partners that have licensed Xencor's technology?
A5: Select partners include Alexion, which is using Xencor's Xtend Fc domain to enhance the halflife of Ultomiris (ravulizumabcwvz), and Amgen, which has licensed rights to the XmAb bispecific Fc domain.
Q6: What is the name of the CD19directed cytolytic antibody developed by Xencor?
A6: The name of the CD19directed cytolytic antibody developed by Xencor is tafasitamabcxix, which is marketed under the brand names Monjuvi and Minjuvi.
Q7: What is the address of Xencor's San Diego office?
A7: The address of Xencor's San Diego office is 12770 El Camino Real, Suite 150 San Diego, CA 92130.
Q8: How can investors contact Xencor?
A8: Investors can contact Xencor through its investor relations department at info@xencor.com or by visiting the company's website for more information on its financials and filings.
A1: The address of Xencor's headquarters is 465 North Halstead Street, Suite 200 Pasadena, CA 91107.
Q2: What type of products does Xencor develop and commercialize?
A2: Xencor develops and commercializes therapeutic antibody drug candidates using its XmAb protein engineering platform, which includes bispecific Fc domains, cytotoxic Fc domains, immune inhibitor Fc domains, and Xtend Fc domains.
Q3: In what industries is Xencor's pipeline focused on treating?
A3: Xencor's pipeline is focused on treating cancer, autoimmune disorders, and infectious diseases.
Q4: What services does Xencor provide to its partners?
A4: Xencor provides a plugandplay approach to creating differentiated antibody drug candidates by licensing its highperformance Fc domains to partners interested in therapeutic targets outside of Xencor's areas of focus. This includes conducting limited research and development to create potential candidates for further development and commercialization by partners.
Q5: Who are some of the select partners that have licensed Xencor's technology?
A5: Select partners include Alexion, which is using Xencor's Xtend Fc domain to enhance the halflife of Ultomiris (ravulizumabcwvz), and Amgen, which has licensed rights to the XmAb bispecific Fc domain.
Q6: What is the name of the CD19directed cytolytic antibody developed by Xencor?
A6: The name of the CD19directed cytolytic antibody developed by Xencor is tafasitamabcxix, which is marketed under the brand names Monjuvi and Minjuvi.
Q7: What is the address of Xencor's San Diego office?
A7: The address of Xencor's San Diego office is 12770 El Camino Real, Suite 150 San Diego, CA 92130.
Q8: How can investors contact Xencor?
A8: Investors can contact Xencor through its investor relations department at info@xencor.com or by visiting the company's website for more information on its financials and filings.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
